These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24965042)

  • 1. Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson's disease.
    Kadoguchi N; Okabe S; Yamamura Y; Shono M; Fukano T; Tanabe A; Yokoyama H; Kasahara J
    BMC Neurosci; 2014 Jun; 15():79. PubMed ID: 24965042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.
    Moon M; Kim HG; Hwang L; Seo JH; Kim S; Hwang S; Kim S; Lee D; Chung H; Oh MS; Lee KT; Park S
    Neurotox Res; 2009 May; 15(4):332-47. PubMed ID: 19384567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission.
    de Boer T
    Int Clin Psychopharmacol; 1995 Dec; 10 Suppl 4():19-23. PubMed ID: 8930006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.
    Hamadjida A; Nuara SG; Veyres N; Frouni I; Kwan C; Sid-Otmane L; Harraka MJ; Gourdon JC; Huot P
    Psychopharmacology (Berl); 2017 Mar; 234(6):905-911. PubMed ID: 28130646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effects of Astilbin on MPTP-induced Parkinson's disease mice: Glial reaction, α-synuclein expression and oxidative stress.
    Zhu YL; Sun MF; Jia XB; Cheng K; Xu YD; Zhou ZL; Zhang PH; Qiao CM; Cui C; Chen X; Yang XS; Shen YQ
    Int Immunopharmacol; 2019 Jan; 66():19-27. PubMed ID: 30419450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 7,8-dihydroxyflavone Ameliorates Motor Deficits Via Suppressing α-synuclein Expression and Oxidative Stress in the MPTP-induced Mouse Model of Parkinson's Disease.
    Li XH; Dai CF; Chen L; Zhou WT; Han HL; Dong ZF
    CNS Neurosci Ther; 2016 Jul; 22(7):617-24. PubMed ID: 27079181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective effects of Danshensu in Parkinson's disease mouse model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Han B; Che X; Zhao Y; Li C; He J; Lu Y; Wang Z; Wang T
    Behav Pharmacol; 2019 Feb; 30(1):36-44. PubMed ID: 29847337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
    Price DA; Martinez AA; Seillier A; Koek W; Acosta Y; Fernandez E; Strong R; Lutz B; Marsicano G; Roberts JL; Giuffrida A
    Eur J Neurosci; 2009 Jun; 29(11):2177-86. PubMed ID: 19490092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicotine improved the olfactory impairment in MPTP-induced mouse model of Parkinson's disease.
    Yang J; Lv DJ; Li LX; Wang YL; Qi D; Chen J; Mao CJ; Wang F; Liu Y; Hu LF; Liu CF
    Neurotoxicology; 2019 Jul; 73():175-182. PubMed ID: 30978411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
    Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
    J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effects of rapamycin on MPTP-induced Parkinsonism in mice.
    Liu K; Shi N; Sun Y; Zhang T; Sun X
    Neurochem Res; 2013 Jan; 38(1):201-7. PubMed ID: 23117422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice.
    Lao CL; Kuo YH; Hsieh YT; Chen JC
    Neurotox Res; 2013 Nov; 24(4):523-31. PubMed ID: 23820985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.
    Ghosh A; Kanthasamy A; Joseph J; Anantharam V; Srivastava P; Dranka BP; Kalyanaraman B; Kanthasamy AG
    J Neuroinflammation; 2012 Oct; 9():241. PubMed ID: 23092448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A disruption mechanism of the molecular clock in a MPTP mouse model of Parkinson's disease.
    Hayashi A; Matsunaga N; Okazaki H; Kakimoto K; Kimura Y; Azuma H; Ikeda E; Shiba T; Yamato M; Yamada K; Koyanagi S; Ohdo S
    Neuromolecular Med; 2013 Jun; 15(2):238-51. PubMed ID: 23292542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of prucalopride in MPTP-induced Parkinson's disease mice: Neurochemistry, motor function and gut barrier.
    Shi Y; Qiao CM; Zhou Y; Wu J; Cui C; Hong H; Jia XB; Huang SB; Yao L; Zhao WJ; Shen YQ
    Biochem Biophys Res Commun; 2021 Jun; 556():16-22. PubMed ID: 33836343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine.
    Haddjeri N; Blier P; de Montigny C
    Int Clin Psychopharmacol; 1995 Dec; 10 Suppl 4():11-7. PubMed ID: 8930005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson's disease.
    Pupyshev AB; Tikhonova MA; Akopyan AA; Tenditnik MV; Dubrovina NI; Korolenko TA
    Pharmacol Biochem Behav; 2019 Feb; 177():1-11. PubMed ID: 30582934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
    Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
    Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin.
    Li C; Biswas S; Li X; Dutta AK; Le W
    J Neurosci Res; 2010 Aug; 88(11):2513-23. PubMed ID: 20623619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.